One-Minute Summary

> Key Conclusions:

> - Multiple 2024–2025 systematic reviews confirm PRP significantly outperforms HA (hyaluronic acid) and placebo, especially over 6–12 months.

> - 2025 dosage Network Meta-Analysis: high-dose PRP (PRP3) yields the best VAS pain and WOMAC function improvement.

> - Leukocyte concentration matters: leukocyte-poor PRP (LP-PRP) generally outperforms leukocyte-rich.

> - Clinical recommendation: Kellgren-Lawrence (KL) II–III patients respond best; KL IV severe disease shows limited response.

> - PRP serves well as a surgery-deferral strategy — highly valuable for middle-aged patients reluctant or not yet ready for knee replacement.

The Knee OA Treatment Ladder

Osteoarthritis (OA) treatment generally follows a stepwise approach by severity:

Why PRP Has a Theoretical Basis for OA

OA pathology is not just "cartilage wear" — it is whole-joint microenvironment inflammation and imbalance:

• Synovitis

• Cartilage matrix degradation

• Subchondral bone remodeling

• Synovial fluid biochemical abnormality

PRP releases high-concentration growth factors targeting these mechanisms:

• TGF-β: chondrocyte proliferation, suppression of IL-1β inflammation

• PDGF: stimulates extracellular matrix synthesis

• IGF-1: promotes type II collagen synthesis

• VEGF: improves subchondral bone perfusion

2024–2025 Latest Evidence

Major Systematic Reviews

A 2024 Annals of Medicine and Surgery comparative effectiveness review of intra-articular treatments concluded:

> PRP outperformed all comparators (HA, corticosteroid, placebo) on three key indicators: success rate, achievement of minimal clinically important difference (MCID), and rates of avoiding re-intervention.

Statistical Significance

The 2025 PLOS One PRP-vs-HA meta-analysis:

• VAS pain: PRP 6-month improvement significantly greater than HA (p Key insight: "PRP works for everyone" oversimplifies. Platelet concentration, number of injections, and leukocyte ratio all significantly affect clinical outcome.

Best Responders

Strong Candidates

KL II–III (moderate) — substantive cartilage to preserve

Pain affecting daily activity but not yet disabling

Not suitable or unwilling for joint replacement

Limited or diminishing HA response

Age 45–65, high activity demand

Poor-Response Scenarios

• KL IV severe (cartilage nearly absent)

• Severe obesity (BMI >35) — mechanical stress overrides biological effect

• Mainly mechanical symptoms (locking, catching) — may need surgery

• Strong inflammatory arthritis (rheumatoid, etc.) — primary disease must be addressed

Protocol Design: Frequency and Intervals

Common protocols:

Three-Shot Protocol

• Every 2–4 weeks × 3 sessions

• Most common; the basis of most studies

• Peak effect at month 6

Single-Dose Intensified

• Single high-dose (PRP3) injection

• Effective in select KL II–III patients

• Re-evaluate at 6 months for additional dose

Maintenance

• Initial 3-shot then booster every 6–12 months

• Suits long-term management plans

PRP + HA Combination: 1 + 1 > 2?

See related article on PRP + HA combined knee strategy.

Briefly:

• PRP + HA outperforms HA alone (high evidence)

• PRP + HA vs PRP alone: evidence mixed; some studies favor combination especially after 6–12 months

• Clinical practice: many physicians use "PRP first, then HA at 4–6 weeks" sequential strategy

Side Effects and Risks

Autologous-blood PRP has high safety:

Common:

• 24–72 hour post-injection joint swelling and pain (initial growth-factor inflammation)

• Transient activity restriction

Rare:

• Infection (with sterile technique Key insight: Many "PRP failures" are preparation or injection-technique problems, not PRP ineffectiveness. Choosing a clinic with full process standardization is essential.

When to Consider Knee Replacement

PRP is not a panacea. These should prompt orthopedic surgical consultation:

• Strict conservative care for 6–12 months still leaves severe pain affecting life

• KL IV severe degeneration

• Mechanical locking, deformity

• Recurrent joint effusion

PRP's role is to defer or avoid surgery — not replace surgery when truly needed.

Conclusion: PRP Is the "Mid-Stage Weapon" for Knee OA

For moderate degeneration with active patients, PRP has progressed from "experimental therapy" 5 years ago to "mainstream non-surgical option" in 2026. The latest evidence clearly shows:

• Overall superiority to HA

• Higher-dose and leukocyte-poor formulations are better

• Excellent surgery-deferral strategy

But PRP is not a miracle, nor for everyone. Professional evaluation, realistic expectations, and standardized preparation are the three success factors.

For evaluation of knee PRP suitability, see our joint injection regenerative service or book a consultation.

Medical References

Comparative effectiveness of intra-articular therapies in knee OA. Annals of Medicine and Surgery. 2024.

Efficacy and safety of intra-articular PRP versus sodium hyaluronate. PLOS One. 2025.

Comparative efficacy of different doses of PRP for knee OA: network meta-analysis. PubMed PMID: 40022138. 2025.

Comprehensive Summary of Meta-Analyses on PRP for Knee OA. Military Medicine. 2024.

PRP Injections for Knee OA: Influence of Platelet Concentration: Meta-analysis. Bensa A, et al. 2025.

Corticosteroids, HA, PRP, and Cell-Based Therapies for Knee OA: Systematic Review. 2025.

Editorial review: Reviewed by Dr. Da-Ru Liu. Last reviewed 2026-04-27.